These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 18029459

  • 1. Influence of growth hormone (GH) receptor deletion of exon 3 and full-length isoforms on GH response and final height in patients with severe GH deficiency.
    Räz B, Janner M, Petkovic V, Lochmatter D, Eblé A, Dattani MT, Hindmarsh PC, Flück CE, Mullis PE.
    J Clin Endocrinol Metab; 2008 Mar; 93(3):974-80. PubMed ID: 18029459
    [Abstract] [Full Text] [Related]

  • 2. The exon 3-deleted/full-length growth hormone receptor polymorphism did not influence growth response to growth hormone therapy over two years in prepubertal short children born at term with adequate weight and length for gestational age.
    Carrascosa A, Audí L, Fernández-Cancio M, Esteban C, Andaluz P, Vilaró E, Clemente M, Yeste D, Albisu MA, Gussinyé M.
    J Clin Endocrinol Metab; 2008 Mar; 93(3):764-70. PubMed ID: 18160465
    [Abstract] [Full Text] [Related]

  • 3. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency.
    Jorge AA, Marchisotti FG, Montenegro LR, Carvalho LR, Mendonca BB, Arnhold IJ.
    J Clin Endocrinol Metab; 2006 Mar; 91(3):1076-80. PubMed ID: 16291702
    [Abstract] [Full Text] [Related]

  • 4. The exon 3-deleted/full-length growth hormone receptor polymorphism and response to growth hormone therapy in growth hormone deficiency and Turner syndrome: a multicenter study.
    Baş F, Darendeliler F, Aycan Z, Çetinkaya E, Berberoğlu M, Sıklar Z, Öcal G, Timirci Ö, Çetinkaya S, Darcan Ş, Gökşen Şimşek D, Bideci A, Cinaz P, Böber E, Demir K, Bereket A, Turan S, Atabek ME, Tütüncüler F, Isbir T, Bozkurt N, Kabataş Eryılmaz S, Uzunhan O, Küçükemre Aydın B, Bundak R.
    Horm Res Paediatr; 2012 Mar; 77(2):85-93. PubMed ID: 22456308
    [Abstract] [Full Text] [Related]

  • 5. Growth hormone (GH) dose, but not exon 3-deleted/full-length GH receptor polymorphism genotypes, influences growth response to two-year GH Therapy in Short Small-for-Gestational-Age Children.
    Carrascosa A, Audí L, Esteban C, Fernández-Cancio M, Andaluz P, Gussinyé M, Clemente M, Yeste D, Albisu MA.
    J Clin Endocrinol Metab; 2008 Jan; 93(1):147-53. PubMed ID: 17925340
    [Abstract] [Full Text] [Related]

  • 6. The growth response to growth hormone (GH) treatment in children with isolated GH deficiency is independent of the presence of the exon 3-minus isoform of the GH receptor.
    Blum WF, Machinis K, Shavrikova EP, Keller A, Stobbe H, Pfaeffle RW, Amselem S.
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4171-4. PubMed ID: 16868057
    [Abstract] [Full Text] [Related]

  • 7. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.
    Binder G, Baur F, Schweizer R, Ranke MB.
    J Clin Endocrinol Metab; 2006 Feb; 91(2):659-64. PubMed ID: 16291706
    [Abstract] [Full Text] [Related]

  • 8. The d3/fl-growth hormone (GH) receptor polymorphism does not influence the effect of GH treatment (66 microg/kg per day) or the spontaneous growth in short non-GH-deficient small-for-gestational-age children: results from a two-year controlled prospective study in 170 Spanish patients.
    Carrascosa A, Esteban C, Espadero R, Fernández-Cancio M, Andaluz P, Clemente M, Audí L, Wollmann H, Fryklund L, Parodi L, Spanish SGA Study Group.
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3281-6. PubMed ID: 16804042
    [Abstract] [Full Text] [Related]

  • 9. The exon 3-deleted/full-length growth hormone receptor polymorphism does not influence the effect of puberty or growth hormone therapy on glucose homeostasis in short non-growth hormone-deficient small-for-gestational-age children: results from a two-year controlled prospective study.
    Audí L, Carrascosa A, Esteban C, Fernández-Cancio M, Andaluz P, Yeste D, Espadero R, Granada ML, Wollmann H, Fryklund L, Spanish SGA Study Group.
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2709-15. PubMed ID: 18445665
    [Abstract] [Full Text] [Related]

  • 10. Influence of the exon 3-deleted/full-length growth hormone (GH) receptor polymorphism on the response to GH replacement therapy in adults with severe GH deficiency.
    Barbosa EJ, Palming J, Glad CA, Filipsson H, Koranyi J, Bengtsson BA, Carlsson LM, Boguszewski CL, Johannsson G.
    J Clin Endocrinol Metab; 2009 Feb; 94(2):639-44. PubMed ID: 19050057
    [Abstract] [Full Text] [Related]

  • 11. Different relationships between the first 2 years on growth hormone treatment and the d3-growth hormone receptor polymorphism in short small-for-gestational-age (SGA) children.
    Dörr HG, Bettendorf M, Hauffa BP, Mehls O, Rohrer T, Stahnke N, Pfäffle R, Ranke MB, German KIGS Group.
    Clin Endocrinol (Oxf); 2011 Nov; 75(5):656-60. PubMed ID: 21623854
    [Abstract] [Full Text] [Related]

  • 12. The interactive effect of GHR-exon 3 and -202 A/C IGFBP3 polymorphisms on rhGH responsiveness and treatment outcomes in patients with Turner syndrome.
    Braz AF, Costalonga EF, Montenegro LR, Trarbach EB, Antonini SR, Malaquias AC, Ramos ES, Mendonca BB, Arnhold IJ, Jorge AA.
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E671-7. PubMed ID: 22278433
    [Abstract] [Full Text] [Related]

  • 13. Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults.
    Meyer S, Schaefer S, Stolk L, Arp P, Uitterlinden AG, Plöckinger U, Stalla GK, Tuschy U, Weber MM, Weise A, Pfützner A, Kann PH.
    Pharmacogenomics; 2009 Oct; 10(10):1599-608. PubMed ID: 19842933
    [Abstract] [Full Text] [Related]

  • 14. Exon 3-deleted/full-length growth hormone receptor polymorphism genotype frequencies in Spanish short small-for-gestational-age (SGA) children and adolescents (n = 247) and in an adult control population (n = 289) show increased fl/fl in short SGA.
    Audí L, Esteban C, Carrascosa A, Espadero R, Pérez-Arroyo A, Arjona R, Clemente M, Wollmann H, Fryklund L, Parodi LA, Spanish SGA Study Group.
    J Clin Endocrinol Metab; 2006 Dec; 91(12):5038-43. PubMed ID: 17003087
    [Abstract] [Full Text] [Related]

  • 15. The impact of the d3-growth hormone receptor (d3-GHR) polymorphism on the therapeutic effect of growth hormone replacement in children with idiopathic growth hormone deficiency in Poland.
    Szmit-Domagalska J, Petriczko E, Drozdzynska M, Adler G, Horodnicka-Jozwa A, Ciechanowicz A, Walczak M.
    Neuro Endocrinol Lett; 2016 Sep; 37(4):282-288. PubMed ID: 27857044
    [Abstract] [Full Text] [Related]

  • 16. Homozygosity of the d3-growth hormone receptor polymorphism is associated with a high total effect of GH on growth and a low BMI in girls with Turner syndrome.
    Binder G, Trebar B, Baur F, Schweizer R, Ranke MB.
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):567-72. PubMed ID: 17973940
    [Abstract] [Full Text] [Related]

  • 17. The growth hormone receptor exon 3-deleted/full-length polymorphism and response to growth hormone therapy in prepubertal idiopathic short children.
    Hellgren G, Glad CA, Jonsson B, Johannsson G, Albertsson-Wikland K.
    Growth Horm IGF Res; 2015 Jun; 25(3):127-35. PubMed ID: 25742716
    [Abstract] [Full Text] [Related]

  • 18. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis.
    Wassenaar MJ, Dekkers OM, Pereira AM, Wit JM, Smit JW, Biermasz NR, Romijn JA.
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3721-30. PubMed ID: 19584188
    [Abstract] [Full Text] [Related]

  • 19. The common exon 3 polymorphism of the growth hormone receptor gene and the effect of growth hormone therapy on growth in Korean patients with Turner syndrome.
    Ko JM, Kim JM, Cheon CK, Kim DH, Lee DY, Cheong WY, Kim EY, Park MJ, Yoo HW.
    Clin Endocrinol (Oxf); 2010 Feb; 72(2):196-202. PubMed ID: 19681916
    [Abstract] [Full Text] [Related]

  • 20. The d3/fl-GH receptor gene polymorphism does not influence quality of life and body composition in GH-deficient adults receiving GH replacement therapy.
    Adetunji OR, MacFarlane IA, Javadpour M, Alfirevic A, Pirmohamed M, Blair JC.
    Eur J Endocrinol; 2009 Oct; 161(4):541-6. PubMed ID: 19605543
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.